629 related articles for article (PubMed ID: 10580413)
1. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats.
Xu G; Stoffers DA; Habener JF; Bonner-Weir S
Diabetes; 1999 Dec; 48(12):2270-6. PubMed ID: 10580413
[TBL] [Abstract][Full Text] [Related]
2. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis.
Li Y; Hansotia T; Yusta B; Ris F; Halban PA; Drucker DJ
J Biol Chem; 2003 Jan; 278(1):471-8. PubMed ID: 12409292
[TBL] [Abstract][Full Text] [Related]
3. Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4.
Tourrel C; Bailbe D; Lacorne M; Meile MJ; Kergoat M; Portha B
Diabetes; 2002 May; 51(5):1443-52. PubMed ID: 11978641
[TBL] [Abstract][Full Text] [Related]
4. Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age.
Tourrel C; Bailbé D; Meile MJ; Kergoat M; Portha B
Diabetes; 2001 Jul; 50(7):1562-70. PubMed ID: 11423477
[TBL] [Abstract][Full Text] [Related]
5. Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas.
Stoffers DA; Kieffer TJ; Hussain MA; Drucker DJ; Bonner-Weir S; Habener JF; Egan JM
Diabetes; 2000 May; 49(5):741-8. PubMed ID: 10905482
[TBL] [Abstract][Full Text] [Related]
6. Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors.
Holst JJ
Expert Opin Emerg Drugs; 2004 May; 9(1):155-66. PubMed ID: 15155141
[TBL] [Abstract][Full Text] [Related]
7. Exendin-4 potentiates insulinotropic action partly via increasing beta-cell proliferation and neogenesis and decreasing apoptosis in association with the attenuation of endoplasmic reticulum stress in islets of diabetic rats.
Kwon DY; Kim YS; Ahn IS; Kim DS; Kang S; Hong SM; Park S
J Pharmacol Sci; 2009 Dec; 111(4):361-71. PubMed ID: 20019445
[TBL] [Abstract][Full Text] [Related]
8. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes.
Nielsen LL; Young AA; Parkes DG
Regul Pept; 2004 Feb; 117(2):77-88. PubMed ID: 14700743
[TBL] [Abstract][Full Text] [Related]
9. Potentiation of insulin secretion and improvement of glucose intolerance by combining a novel G protein-coupled receptor 40 agonist DS-1558 with glucagon-like peptide-1 receptor agonists.
Nakashima R; Yano T; Ogawa J; Tanaka N; Toda N; Yoshida M; Takano R; Inoue M; Honda T; Kume S; Matsumoto K
Eur J Pharmacol; 2014 Aug; 737():194-201. PubMed ID: 24858371
[TBL] [Abstract][Full Text] [Related]
10. Role of endogenous glucagon-like peptide-1 in islet regeneration after partial pancreatectomy.
De León DD; Deng S; Madani R; Ahima RS; Drucker DJ; Stoffers DA
Diabetes; 2003 Feb; 52(2):365-71. PubMed ID: 12540609
[TBL] [Abstract][Full Text] [Related]
11. Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats.
Pospisilik JA; Martin J; Doty T; Ehses JA; Pamir N; Lynn FC; Piteau S; Demuth HU; McIntosh CH; Pederson RA
Diabetes; 2003 Mar; 52(3):741-50. PubMed ID: 12606516
[TBL] [Abstract][Full Text] [Related]
12. Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice.
Wang Q; Brubaker PL
Diabetologia; 2002 Sep; 45(9):1263-73. PubMed ID: 12242459
[TBL] [Abstract][Full Text] [Related]
13. beta-Cell Pdx1 expression is essential for the glucoregulatory, proliferative, and cytoprotective actions of glucagon-like peptide-1.
Li Y; Cao X; Li LX; Brubaker PL; Edlund H; Drucker DJ
Diabetes; 2005 Feb; 54(2):482-91. PubMed ID: 15677506
[TBL] [Abstract][Full Text] [Related]
14. Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats.
Perfetti R; Zhou J; Doyle ME; Egan JM
Endocrinology; 2000 Dec; 141(12):4600-5. PubMed ID: 11108273
[TBL] [Abstract][Full Text] [Related]
15. Combined Treatment with Bone Marrow-Derived Mesenchymal Stem Cells and Exendin-4 Promotes Islet Regeneration in Streptozotocin-Induced Diabetic Rats.
Song X; Sun X; Hao H; Han Q; Han W; Mu Y
Stem Cells Dev; 2021 May; 30(9):502-514. PubMed ID: 33677993
[TBL] [Abstract][Full Text] [Related]
16. Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations.
Greig NH; Holloway HW; De Ore KA; Jani D; Wang Y; Zhou J; Garant MJ; Egan JM
Diabetologia; 1999 Jan; 42(1):45-50. PubMed ID: 10027577
[TBL] [Abstract][Full Text] [Related]
17. Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro.
Parkes DG; Pittner R; Jodka C; Smith P; Young A
Metabolism; 2001 May; 50(5):583-9. PubMed ID: 11319721
[TBL] [Abstract][Full Text] [Related]
18. Effects of exendin-4 on glucose tolerance, insulin secretion, and beta-cell proliferation depend on treatment dose, treatment duration and meal contents.
Arakawa M; Ebato C; Mita T; Hirose T; Kawamori R; Fujitani Y; Watada H
Biochem Biophys Res Commun; 2009 Dec; 390(3):809-14. PubMed ID: 19836346
[TBL] [Abstract][Full Text] [Related]
19. The multifaceted potential of glucagon-like peptide-1 as a therapeutic agent.
Lam NT; Kieffer TJ
Minerva Endocrinol; 2002 Jun; 27(2):79-93. PubMed ID: 11961501
[TBL] [Abstract][Full Text] [Related]
20. The effects of exendin-4 treatment on graft failure: an animal study using a novel re-vascularized minimal human islet transplant model.
Sahraoui A; Winzell MS; Gorman T; Smith DM; Skrtic S; Hoeyem M; Abadpour S; Johansson L; Korsgren O; Foss A; Scholz H
PLoS One; 2015; 10(3):e0121204. PubMed ID: 25793295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
